Intimal sarcoma is a rare, aggressive malignancy that mimics thromboembolic disease and is highly resistant to standard treatments, highlighting the need for novel combination therapies.
Intimal sarcoma is an extremely rare and aggressive malignancy that has a very poor prognosis. Mimicking thromboembolic disease, diagnosis and treatment can be delayed. Surgery is the mainstay of treatment but is seldom curative. The disease is highly resistant to cytotoxic and targeted treatment. Given the fact that intimal sarcoma commonly expresses more than 1 molecular target, combination therapy might be an option, although toxicity may be a limitation.
Dievel et al. (Sun,) studied this question.